Aflac Incorporated Stock Outlook: Is Wall Street Bullish or Bearish?
Aflac (AFL) stock has lagged the S&P 500 over 52 weeks, rising 18.3% vs 21.3%, and is up 11% YTD vs 13.2% for SPX. After Q2 2026 results, shares fell 1.6% on adjusted EPS of $1.75 and revenue of $4.1B. Analysts expect 2026 adjusted EPS of $7.05 (-5.9% YoY). Consensus is Hold; TD Cowen raised its price target to $110.
How this was made
The 30-second read
Why it matters
Q2 2026 results were weaker than expected due to a stronger dollar and a 12.7% year-over-year decline in net premiums earned in Japan, while analysts still rate the stock mostly as Hold.
Market read
This is a company-specific earnings and analyst-target update that can influence near-term positioning, but it is not a fresh disclosure beyond the already-reported Q2 results.
What to watch
The article does not quantify management guidance or capital/underwriting changes; traders may need to focus on forward premium trends and FX hedging rather than the single-quarter decline.
Background
Aflac is a supplemental health insurer with major exposure to the U.S. and Japan, so FX and Japan premium trends can materially affect reported earnings.
Ticker impact
Aflac shares fell after Q2 2026 results, citing weaker-than-expected adjusted EPS and revenue plus a stronger dollar impact.
Choppy-to-soft trading is likely until investors digest the Japan net premium decline and FX headwinds; upside may be capped near the raised PT until next earnings.
The article provides concrete Q2 figures (adjusted EPS $1.75, revenue $4.1B), identifies FX and Japan premium drivers, and notes a specific TD Cowen PT increase to $110 while the Street consensus remains Hold.
Market effects
Supplemental health insurers may remain sensitive to FX translation and Japan premium trends, affecting sector earnings expectations.
Japan-linked premium weakness and yen/dollar moves are highlighted as key swing factors for Aflac’s results.
Limited broader market spillover; the story is company-specific to Aflac’s Japan exposure and FX sensitivity.
Counterpoint
The TD Cowen price-target raise and the stock trading above the mean target suggest the market may already be pricing in a recovery, making the Q2 miss less decisive than it appears.
Key entities
- companyAflac Incorporated
Subject of the article; Q2 2026 results, FX impact, Japan premium decline, and analyst rating/price-target context are discussed.
- analyst_firmTD Cowen
Raised Aflac’s price target to $110 while keeping a Hold rating.
